Tag Archives: respiratory diseases

Novartis division Sandoz expands respiratory medicines portfolio with the acquisition of British company Coalesce Product Development Limited

Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide Acquisition … Read the full press release

Second Phase 3 trial for Dupixent/Dupilumab: the medicine can significantly reduce itch and skin lesions in patients with uncontrolled prurigo nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release

Roche study combining Esbriet and nintedanib treatment: majority of the patients tolerated the combination treatment

New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be associated with a reduction of multiple … Read the full press release

Spanish pharmaceutical company Almirall released its H1 2013 financial results

Barcelona,  05-8-2013 — /EuropaWire/ — Almirall’s H1: Executing on growth platforms, financial delivery on track Financial performance in line with guidance Aclidinium now available in 13 countries with five new launches planned before year’s end US/EU filings of aclidinium/formoterol combination are … Read the full press release